India vs Venezuela: Average cost of drugs for extensively drug-resistant tuberculosis
India
1,203 constant 2022 US$
in 2024
Venezuela
1,234 constant 2022 US$
in 2024
India rank
39th
Venezuela rank
38th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- India
- Venezuela
How they compare
Venezuela currently reports 1,234 constant 2022 US$ against 1,203 constant 2022 US$ in India, a difference of 31 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was India ahead.
India ranks 39th and Venezuela ranks 38th of 56 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Venezuela | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,000 constant 2022 US$ | 4,182 constant 2022 US$ | 2,818 constant 2022 US$ | India |
| 2020s | 2,104 constant 2022 US$ | 1,673 constant 2022 US$ | 430.2 constant 2022 US$ | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, India or Venezuela?
- Venezuela, at 1,234 constant 2022 US$ against 1,203 constant 2022 US$ in India as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between India and Venezuela?
- 31 constant 2022 US$, with Venezuela ahead.
- How many years of comparable data are there for India and Venezuela?
- 8 years are reported by both, from 2017 to 2024.
- How do India and Venezuela rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- India ranks 39th and Venezuela ranks 38th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.